Familial idiopathic hyperphosphatasia (FIH): Response to long-term treatment with pamidronate (APD)
- 30 November 1992
- journal article
- case report
- Published by Elsevier in Bone and Mineral
- Vol. 19 (2), 175-184
- https://doi.org/10.1016/0169-6009(92)90924-3
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Intravenous aminopropylidene bisphosphonate (APD) in the treatment of paget's bone diseaseJournal of Bone and Mineral Research, 1987
- Hyperphosphatasemia in an AdultPublished by Wolters Kluwer Health ,1986
- Efficacy of the bisphosphonate APD∗∗(Note on the nomenclature: Traditional abbreviations for identifying compounds have been used in the text. According to IUPAC: Nomenclature of Organic Chemistry, Sections A-H (Pergamon Press, Oxford, 1979), the new abbreviations are as follows: APD = AHP1BP: 3-amino-1-hydroxypropylidene-1,1-bisphosphonate EHDP = HEBP: 1-hydroxyethylidene-1,1-bisphosphonate Cl2MDP = Cl2MBP: Dichloromethylenebisphosphonate. in the control of Paget's bone diseaseBone, 1985
- Familial hyperphosphatasemia: diagnosis in early infancy and response to human thyrocalcitonin therapyAmerican Journal of Roentgenology, 1979
- Calcitonin treatment in hereditary bone dysplasia with hyperphosphatasemia: a radiographic and histologic study of boneAmerican Journal of Roentgenology, 1977
- Healing of the bones in juvenile Paget's disease treated by human calcitoninThe British Journal of Radiology, 1974
- Hereditary hyperphosphatasia: Studies of three siblingsAmerican Journal Of Medicine, 1969
- Modifications of a specific assay for hydroxyproline in urineAnalytical Biochemistry, 1967
- Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I.Archives of Disease in Childhood, 1966
- Fragile bones and macrocraniumThe Journal of Pediatrics, 1956